KRMD Stock Forecast & Price Target

KORU Medical Systems Inc is poised for continued growth, with management projecting mid-teens growth in 2025 and potential upside to upper-teens or low-twenties percentages, reflecting a robust market position within the immunoglobulin therapy sector. The company has reported significant improvements in its gross margin, achieving a nearly 900 basis point expansion to 65%, illustrating effective operational performance and cost management. Furthermore, after a series of solid quarterly performances, management raised its full-year revenue guidance to a range of $32.75 million to $33.25 million, indicating an anticipated year-over-year increase of 15-17%, which bodes well for KORU's financial health and growth trajectory.

KORU Medical Systems has reported declining revenue growth, which raises concerns about its ability to capture market share in a competitive healthcare landscape. Additionally, the company has shown increasing operating expenses, which are outpacing revenue growth and impacting overall profitability. Lastly, the financial metrics indicate a potential cash flow strain, suggesting difficulties in sustaining operations without additional financing or improved sales performance.